Evidence map›Paper›PMID 29867130›Full record

ArticleCell death and differentiation2018

USP20 positively regulates tumorigenesis and chemoresistance through β-catenin stabilization.

Chenming Wu, Kuntian Luo, Fei Zhao, Ping Yin, Ying Song, Min Deng, Jinzhou Huang, Yuping Chen, Lei Li, SeungBaek Lee and 9 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Cell death and differentiation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 96 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Cardiomyocyte-Derived USP20 Attenuates Diabetic Cardiomyopathy by Facilitating the Degradation of STING and Mitigating STING-Mediated Inflammation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Acta pharmaceutica Sinica. B · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Chenming WuResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Kuntian LuoResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Fei ZhaoDepartment of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Ping YinDepartment of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Ying SongDepartment of Pathology, East Hospital, Shanghai, 200120, China.
Min DengDepartment of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Jinzhou HuangDepartment of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Yuping ChenResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
Lei LiResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai, 200120, China.
SeungBaek LeeDepartment of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
JungJin KimDepartment of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Qin ZhouDepartment of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Xinyi TuDepartment of Oncology, Mayo Clinic, Rochester, MN, 55905, USA.
Somaira NowsheenMayo Clinic Medical Scientist Training Program, Mayo Clinic School of Medicine and Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, 55905, USA.
Qifeng LuoDepartment of Gastrointestinal Surgery, Shanghai East Hospital, School of Medicine, Tongji University Shanghai, 200120, Shanghai, P. R. China.
Xiumei GaoTianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 300193, Tianjin, China.
Zhenkun LouDepartment of Oncology, Mayo Clinic, Rochester, MN, 55905, USA. Lou.zhenkun@mayo.edu.ORCID http://orcid.org/0000-0003-1938-3091
Zhongmin LiuResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai, 200120, China. Zhongmin_Liu@sina.com.
Jian YuanResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai, 200120, China. Yuanjian229@hotmail.com.
Mayo Clinic in Arizona · USTongji University · CNMayo Clinic · USShanghai East Hospital · CNTianjin University of Traditional Chinese Medicine · CN

Funding

Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Medical Scientist Traning Program at Mayo ClinicT32GM065841 · NIGMS · MAYO CLINIC ROCHESTER · PI KAUFMANN, SCOTT H, SCHIMMENTI, LISA A · 2003 to 2022
$5.8M
Ubiquitination and the DNA Damage Response PathwayR01CA130996 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2008 to 2018
$3.3M
Regulation of homologous recombination and cancer cell response to chemoradiotherapyR01CA203561 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2016 to 2020
$1.8M
Deubiquitinases in regulation of BRCA1 pathwayR01CA203971 · NCI · MAYO CLINIC ROCHESTER · PI KAUFMANN, SCOTT H, LOU, ZHENKUN · 2016 to 2020
$1.8M
The Role of WSB1 in TumorigenesisR01CA189666 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2014 to 2018
$1.6M
NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA130996NCI NIH HHS R01 CA189666NCI NIH HHS R01 CA203561NCI NIH HHS R01 CA203971NIGMS NIH HHS T32 GM065841
6 · The paper itself

Abstract

β-catenin is a major transcriptional activator of the canonical Wnt/β-catenin signaling pathway. It is important for a series of biological processes including tissue homeostasis, and embryonic development and is involved in various human diseases. Elevated oncogenic activity of β-catenin is frequently observed in cancers, which contributes to survival, metastasis and chemo-resistance of cancer cells. However, the mechanism of β-catenin overexpression in cancers is not well defined. Here we demonstrate that the deubiquitination enzyme USP20 is a new regulator of the Wnt/β-catenin signaling pathway. Mechanistically, USP20 regulates the deubiquitination of β-catenin to control its stability, thereby inducing proliferation, invasion and migration of cancer cells. High expression of USP20 correlates with increased β-catenin protein level in multiple cancer cell lines and patient samples. Moreover, knockdown of USP20 increases β-catenin polyubiquitination, which enhances β-catenin turnover and cell sensitivity to chemotherapy. Collectively, our results establish the USP20-β-catenin axis as a critical regulatory mechanism of canonical Wnt/β-catenin signaling pathway with an important role in tumorigenesis and chemo response in human cancers.

Indexed as

Drug Resistance, NeoplasmAnimalsAntineoplastic Agentsbeta CateninCell Line, TumorCell MovementCell SurvivalCell Transformation, NeoplasticFemaleHEK293 CellsHumansLeupeptinsMiceMice, NudeNeoplasmsRNA InterferenceAntineoplastic Agentsbenzyloxycarbonylleucyl-leucyl-leucine aldehydebeta CateninLeupeptinsRNA, Small InterferingUbiquitin ThiolesteraseUSP20 protein, human

Identifiers

PMID29867130
PMCPMC6180113
OpenAlexW2806311392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.